"Let's say you wake up really hungry," says Lembas CTO Dr. Zohar Barbash. "You take the peptide and feel like you have just ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they ...

GIP (red),  glucagon (violet) and PYY (green). Each hormone targets its own receptor. The effect of each receptor on the body are indicated using the same color code. The tetra-agonist compound ...

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure?affecting more than 250 million people worldwide?Echosens, ...

GLP-1 drugs “alter taste perception” and "disrupt the perception of sweetness, bitterness, fatty foods and even mouthfeel”, a ...

Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. For the first time at an international conference, Caliway ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

Lembas is a new b2b ingredient business that makes a peptide powder that targets the GLP-1 hormone for weight loss ...

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.